康心胶囊在冠心病二级预防中的作用  

The effects of "Kangxin capsule" on the secondary prevention in patients with coronary heart disease

作　　者：陈才旺 贾萍 王宏艳 王延梅 

机构地区：[1]本溪市中心医院,辽宁省本溪市117000

出　　处：《中国厂矿医学》2006年第1期10-12,共3页Chinese Medicine of Factory and Mine

摘　　要：目的观察“康心胶囊”在冠心病二级预防中的作用及疗效。方法将493例冠心病病人分为对照组和治疗组，进行了平均3．5年的观察研究。全部入选病例均给予规范的综合治疗，治疗组加服康心胶囊。观察康心胶囊对血脂，心功能、心脏结构及冠心病事件的影响。结果2组患者在平均治疗3．5年后。与治疗前相比，治疗组与对照组的血脂均有明显改善（P〈0．05-〈0．01）、心功能改善（P〈0．01-〈0．05）、左室舒张末径、左室收缩末径、左室舒张末容积、左室收缩末容积、左室射血分数均有改善（P〈0．01），但治疗组优于对照组（P〈0．05）。冠心病事件中，非致死性心肌梗死、心脏性死亡、复发性心绞痛、心力衰竭、需做PTCA／CABG、再住院治疗、心律失常、脑卒中、非心脏性死亡、全因死亡治疗组明显少于对照组（P〈0．05）。2组药物不良反应无统计学差异（P〉0．05）。结论康心胶囊治疗能进一步降低血脂、减轻左心室重构、改善左心功能、减少冠心病事件的发生。Objective To observe the effects of the ＂ Kangxin capsule＂ on the secondary prevention in patients with coronary heart disease. Methods 493 patients with coronary heart disease were randomly divided into the ＂Kangxin capsule＂ group and the conventional group. All patients were given regular and comprehensive treatment. Before and after average 3.5 years treatment, the blood lipids, heart function, heart structure,and coronary affairs were determined. Results The blood lipids were obviouly lowered in both groups after treatment （ P 〈 0. 05 or P 〈 0. 01 ）. The heart function were significantly strengthened （ P 〈 0. 01 or P 〈 0. 05 ）, and LVDD, LVSD, LVDV, LVSV, LVEF were improved （ P 〈 0. 01 ）, but the ＂Kangxin capsule＂ group exceeded the conventional group （ P 〈 0. 05 ）. The occurrence of coronary affairs were lower in ＂Kangxin capsule＂ group than that in conventional group （ P 〈 0. 05） including non-deadly myocardial infarction,heart death, repeating angina peetoris, heart failure, need to do PTCA/CABG, re-hospitalization treatment, arrhythmia, brain stroke,non - heart death,and all faeturs death. Those of adverse drug reaction had no siguificant difference. Conclusions The＂ Kangxin capsule＂ may lower the blood lipids,lighten left ventrieular restructure,improve left ventricular function, and reduce the occurrence of coronary affairs.

关 键 词：冠心病 康心胶囊 二级预防 

分 类 号：R541.4[医药卫生—心血管疾病] R286.0[医药卫生—内科学]